收稿日期: 2023-09-27
网络出版日期: 2024-03-26
基金资助
国家自然科学基金资助项目(81960118);贵州省科技计划项目(黔科合基础［2020］1Y300);贵州省卫生健康委科学技术基金项目(gzwkj2022-180)
The diagnostic value of miR⁃571 levels in blood from the peripherals in liver fibrosis
Received date: 2023-09-27
Online published: 2024-03-26
目的 通过检测肝纤维化患者外周血中miR-571的表达，探讨miR-571水平对肝纤维化的诊断意义。 方法 选取2022年12月至2023年9月诊断为肝纤维化的患者40例（肝纤维化组）、肝炎患者40例（肝炎组）和健康对照者40例（健康对照组）作为研究对象。采用实时荧光定量PCR检测外周血中miR-571的表达水平，分析各组中miR-571的相对表达量。使用Spearman相关性分析miR-571与临床常见指标的相关性。通过二元logistic回归构建多变量诊断模型，并绘制ROC曲线评价miR-571和多变量诊断模型对肝纤维化的诊断能力。 结果 肝纤维化组中miR-571的表达水平显著高于健康对照组和肝炎组，差异有统计学意义（P < 0.001）。Spearman相关性分析显示，miR-571的表达水平与ALT、APRI评分和FIB-4指数呈正相关（r = 0.23、0.30、0.22，P < 0.05），与PLT呈负相关（r = -0.19，P < 0.05）。logistic回归分析得出miR-571和FIB-4指数是肝纤维化的独立危险因素。ROC曲线结果显示miR-571诊断纤维化的AUC为0.91（95%CI：0.85 ~ 0.96），miR-571联合FIB-4指数诊断肝纤维化的AUC为0.94（95%CI：0.90 ~ 0.98）。 结论 肝纤维化患者的外周血中miR-571表达显著升高，联合FIB-4指数对肝纤维化具有一定临床诊断价值。
唐娟 , 李燚 , 翟丽琼 , 刘邵雯 , 申涌 , 丛硕 , 刘咏梅 . 外周血miR-571水平对肝纤维化的诊断价值[J]. 实用医学杂志, 2024 , 40(5) : 653 -657 . DOI: 10.3969/j.issn.1006-5725.2024.05.011
Objective To study the diagnostic value of miR-571 for liver fibrosis by detecting miR-571 expression in the peripheral blood of patients with liver fibrosis. Methods From December 2022 to September 2023， 40 patients with liver fibrosis， 40 patients with chronic hepatitis， and 40 healthy controls were chosen as research subjects. The expression level of miR-571 in peripheral blood was detected using a real-time quantitative polymerase chain reaction， and the relative expression of miR-571 in each group was evaluated. The Spearman correlation method was utilized to examine the relationship between miR-571 and clinical detection indices. To assess the capacity of miR-571 and the multivariate diagnostic model to identify liver fibrosis， binary logistic regression was used to create a multivariate diagnostic model， and ROC curves were generated. Results The expression of miR-571 was significantly higher in the liver fibrosis group than in the healthy control and hepatitis groups， and the difference was statistically significant （P < 0.001）. The expression level of miR-571 was positively connected with ALT， APRI score， and FIB-4 index （r = 0.23， 0.30， 0.22， P < 0.05） and negatively correlated with PLT （r = -0.19， P < 0.05） according to Spearman correlation analysis. Logistic regression research revealed that miR-571 and the FIB-4 index were independent risk factors for liver fibrosis. The AUC for miR-571 to diagnose fibrosis was 0.91 （95% CI： 0.85 ~ 0.96）， while the AUC for miR-571 paired with the FIB-4 index was 0.94 （95% CI： 0.90 ~ 0.98）. Conclusion MiR-571 expression was shown to be considerably higher in the peripheral blood of hepatic fibrosis patients， and the combined FIB-4 index offers some clinical diagnostic value for hepatic fibrosis.
Key words： liver fibrosis; miR-571; diagnosis
| 1 | LIEDTKE C， NEVZOROVA Y A， LUEDDE T， et al. Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease ［J］. Front Med （Lausanne）， 2021， 8： 814496. doi:10.3389/fmed.2021.814496 |
| 2 | ROEHLEN N， CROUCHET E， BAUMERT T F. Liver Fibrosis： Mechanistic Concepts and Therapeutic Perspectives ［J］. Cells， 2020， 9（4） ：875. doi:10.3390/cells9040875 |
| 3 | JANGRA A， KOTHARI A， SARMA P， et al. Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis ［J］. Cells， 2022， 11（9） ：1500. doi:10.3390/cells11091500 |
| 4 | TADOKORO T， MORISHITA A， MASAKI T. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA ［J］. Int J Mol Sci， 2021， 22（15） ：8139. doi:10.3390/ijms22158139 |
| 5 | HAEP N， FLORENTINO R M， SQUIRES J E， et al. The Inside-Out of End-Stage Liver Disease： Hepatocytes are the Keystone ［J］. Semin Liver Dis， 2021， 41（2）： 213-224. doi:10.1055/s-0041-1725023 |
| 6 | CHIMORIYA R， PIYA M K， SIMMONS D， et al. The Use of Two-Dimensional Shear Wave Elastography in People with Obesity for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease ［J］. J Clin Med， 2020， 10（1） ：95. doi:10.3390/jcm10010095 |
| 7 | COSTANTINO A， PIAGNANI A， NANDI N， et al. Reproducibility and diagnostic accuracy of pocket-sized ultrasound devices in ruling out compensated cirrhosis of mixed etiology ［J］. Eur Radiol， 2022， 32（7）： 4609-4615. doi:10.1007/s00330-022-08572-2 |
| 8 | 陈永刚， 黄刚. 血清miR-134及miR-301水平对慢性丙型肝炎肝纤维化的诊断价值 ［J］. 实用医学杂志， 2022， 38（10）： 1276-1279. doi:10.3969/j.issn.1006-5725.2022.10.020 |
| 9 | XINGTAO Z， XINYAN X， ZHIFU C， et al. microRNAs-based diagnostic and therapeutic applications in liver fibrosis ［J］. Wiley Interdiscip Rev RNA， 2022， 14（4）：e1773. doi:10.1002/wrna.1773 |
| 10 | LI H， LIU T， YANG Y， et al. Interplays of liver fibrosis-associated microRNAs： Molecular mechanisms and implications in diagnosis and therapy ［J］. Genes Dis， 2023， 10（4）： 1457-1469. doi:10.1016/j.gendis.2022.08.013 |
| 11 | OURA K， MORISHITA A， MASAKI T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review ［J］. Int J Mol Sci， 2020， 21（21）：8362. doi:10.3390/ijms21218362 |
| 12 | RODERBURG C， MOLLNOW T， BONGAERTS B， et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis ［J］. PLoS One， 2012， 7（3）： e32999. doi:10.1371/journal.pone.0032999 |
| 13 | 王贵强， 王福生， 庄辉， 等. 慢性乙型肝炎防治指南（2019年版） ［J］. 中国病毒病杂志， 2020， 10（1）： 1-25. |
| 14 | CONG S， LIU Y， LI Y， et al. MiR-571 affects the development and progression of liver fibrosis by regulating the Notch3 pathway ［J］. Sci Rep， 2021， 11（1）： 21854. doi:10.1038/s41598-021-00638-3 |
| 15 | ULLAH H， TIAN Y， ARBAB S， et al. Circulatory microRNAs in helminthiases： Potent as diagnostics biomarker， its potential role and limitations ［J］. Front Vet Sci， 2022， 9： 1018872. doi:10.3389/fvets.2022.1018872 |
| 16 | WANG Y， HE B， ZHANG L， et al. Physicochemical properties of superfine grinding-microwave modified artichoke soluble dietary fiber and their alleviation of alcoholic fatty liver in mice ［J］. Front Nutr， 2023， 10： 1253963. doi:10.3389/fnut.2023.1253963 |
| 17 | FENG L L， LIU R Y， AN K， et al. TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease ［J］. Sci Rep， 2023， 13（1）： 6382. doi:10.1038/s41598-023-33564-7 |
| 18 | PESCHEL G， GRIMM J， GüLOW K， et al. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury ［J］. Diagnostics （Basel）， 2020， 10（11）：974. doi:10.3390/diagnostics10110974 |
/
| 〈 |
|
〉 |